Francesco Patti1, Angelo Pappalardo2, Enrico Montanari3, Ilaria Pesci3, Valeria Barletta4, Carlo Pozzilli4. 1. Department DANA GF Ingrassia, Neurosciences Section, Multiple Sclerosis Centre, University of Catania, Catania, Italy. Electronic address: patti@unict.it. 2. Department of Rehabilitation, S. Marta & S. Venera Hospital, Acireale, Catania, Italy. 3. Multiple Sclerosis Centre, Unit of Neurology, Fidenza- S. Secondo Hospital, Fidenza, Parma, Italy. 4. Multiple Sclerosis Centre, S. Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Abstract
PURPOSE: The impact of interferon beta (IFNβ) therapy on a patient's quality of life (QoL) has not been completely clarified. This multicenter, independent, observational and longitudinal study was aimed to evaluate the impact of different pharmaceutical formulations of IFNβ-1a on QoL in patients affected by relapsing-remitting multiple sclerosis (RRMS). METHODS: The multiple sclerosis quality of life-54 questionnaire was used to assess patients' QoL. RESULTS: 394 (66%) patients completed the two-year study; 152 were treated withIFNβ-1a i.m. weekly injected (group a), 152 with IFNβ-1a 44 μg s.c. injected three times a week (group b) and 90 were untreated (group c). After two years, a significant increase was found in the physical health composite score (Δ = +3.1 in group a, Δ = +3 in group b, p < 0.05 in both), mental health composite score (Δ = +4.7 in group a, Δ = +5.5 in group b, p < 0.001 in both), in eight MSQoL sub-items of group a and in seven sub-items in group b. Conversely, the untreated group showed a slight decrease in seven domains. The variable "therapy with DMDs" was associated with improved QoL. CONCLUSION: QoL of RRMS could be improved by IFNβ-1a treatment, despite natural history data which seem to demonstrate that QoL could get worse over the time.
RCT Entities:
PURPOSE: The impact of interferon beta (IFNβ) therapy on a patient's quality of life (QoL) has not been completely clarified. This multicenter, independent, observational and longitudinal study was aimed to evaluate the impact of different pharmaceutical formulations of IFNβ-1a on QoL in patients affected by relapsing-remitting multiple sclerosis (RRMS). METHODS: The multiple sclerosis quality of life-54 questionnaire was used to assess patients' QoL. RESULTS: 394 (66%) patients completed the two-year study; 152 were treated with IFNβ-1a i.m. weekly injected (group a), 152 with IFNβ-1a 44 μg s.c. injected three times a week (group b) and 90 were untreated (group c). After two years, a significant increase was found in the physical health composite score (Δ = +3.1 in group a, Δ = +3 in group b, p < 0.05 in both), mental health composite score (Δ = +4.7 in group a, Δ = +5.5 in group b, p < 0.001 in both), in eight MSQoL sub-items of group a and in seven sub-items in group b. Conversely, the untreated group showed a slight decrease in seven domains. The variable "therapy with DMDs" was associated with improved QoL. CONCLUSION: QoL of RRMS could be improved by IFNβ-1a treatment, despite natural history data which seem to demonstrate that QoL could get worse over the time.
Authors: J Nicholas Brenton; Diana Lehner-Gulotta; Emma Woolbright; Brenda Banwell; A G Christina Bergqvist; Shanshan Chen; Rachael Coleman; Mark Conaway; Myla D Goldman Journal: J Neurol Neurosurg Psychiatry Date: 2022-04-13 Impact factor: 13.654